در بيماران همودياليزي شهر تبريز در سال 3831 E بررسي شيوع آنتي بادي ضد هپاتيت

Anti Hepatitis E Virus Antibody in hemodialysis patients: A seroepidemiological survey in Iran

Back ground: The hepatitis E virus (HEV) has a global distribution and is known to have caused large waterborne epidemics of icteric hepatitis. Transmission is generally via the fecal oral route. Some reports have suggested parenterally transmission of HEV. Anti-HEV prevalence data among chronic hemodialysis (HD) patients are few and given conflicting results. Materials and Methods: This cross-sectional study was conducted in August of 2004.We tested 324 chronic HD patients attending three different units in the city of Tabriz, in the northwestern part of Iran, for anti-REV antibody. A specific solid- phase enzyme-linked immunoassay (Diapro, Italy) was used. Results:The overall seroprevalence of hepatitis E was 7.4%( 95% Ci: 4.6%-10.6%). The prevalence rate of HBV and HCV infection were 4.6% (95% CI: 2.3%-6.9%) and 20.4% (95% Ci: 16%-24.8%) respectively. The seroprevalence of anti-REV antibody among chronic HD patients was associated significantly with age. No statistically significant association was observed between HEV seropositivity and other variables. Conclusion. We observed a high anti-HEV prevalence; there was no association between REV and blood borne infections (HBV, HCV, HIV) in our HD patients; most anti -REV positive patients we found were probably related to a local infection by REV. This is the first report concerning seroepidemiology of HEV infection in a large cohort of chronic HD individuals in Iran.